Epithalon vs NAD+
Epithalon is a synthetic tetrapeptide, Ala-Glu-Asp-Gly, derived from the pineal extract preparation Epithalamin, whose literature reports telomerase induction, telomere elongation in cultured human cells, circadian and pineal gene modulation and lifespan extension in flies and rodents. NAD+ is not a peptide at all but a redox cofactor and enzyme substrate for sirtuins, PARPs and CD38, studied in humans almost entirely through its oral precursors nicotinamide riboside and nicotinamide mononucleotide. The two are set side by side because both are marketed against the hallmarks of ageing, one aimed at telomere attrition and the other at metabolic decline. No study has administered Epithalon and NAD+ or its precursors in the same experiment, in any model. What exists is a body of ageing reviews and one mouse oocyte study that discuss both compounds within a single frame without testing either against the other.
No study has compared them directly.
Everything below is drawn from separate studies that used different models, endpoints and species. That is a real limit on what can be concluded, not a formality.
No published study has tested Epithalon against NAD+ or an NAD+ precursor in the same experiment, in vitro, in an animal model or in humans. Searches of PubMed and Europe PMC returned no controlled comparison and no combination study. The records that engage both are of two kinds. The first is geroprotection review literature: narrative and systematic reviews of ageing interventions that catalogue the AEDG tetrapeptide alongside nicotinamide riboside, nicotinamide mononucleotide or NAD+ decline as separate entries in one landscape, sometimes in the same table of candidate geroprotectors. The most useful of these is a 2023 systematic review of sex differences in lifespan interventions, which tabulated the rodent lifespan results for Epithalon and for nicotinamide riboside side by side, together with the sexes in which each was tested. The second is a 2025 mouse study of oocyte senescence whose discussion cited published concentration-dependent failures of both nicotinamide mononucleotide and Epitalon in oocyte models while administering neither. Any comparison between the two is therefore indirect, assembled from separate studies using different species, endpoints and eras of methodology.
The 8 publications that cover both
- 01Systematic review2023
Sex differences in pharmacological interventions and their effects on lifespan and healthspan outcomes: a systematic review
Knufinke M, et al. · Frontiers in Aging · systematic review of pharmacological lifespan and healthspan interventions in rodents, tabulated by compound, mouse strain, sex and healthspan measure
The review tabulated Epithalon and nicotinamide riboside as separate interventions in one dataset. Epithalon, given by injection to female CBA mice, was recorded as increasing mean lifespan and improving several healthspan measures, and the authors noted that Vilon and Epithalon were both shown to significantly improve female lifespan without male comparison data. For nicotinamide riboside the record was mixed: one study reported increased maximal lifespan in C57BL/6 mice without specifying sex, while a later study in UM-HET3 mice found no lifespan effect in either sex, and nicotinamide improved glucose metabolism without extending lifespan. The review's conclusion was methodological, that single-sex and single-strain designs limit what any of these results support.
- 02Animal in vivo2025
Nano-encapsulated senolytic cocktail attenuates germ cell senescence in female mice
Guan Y, et al. · Cellular and Molecular Life Sciences · nano-encapsulated dasatinib and quercetin senolytic cocktail in cultured post-ovulatory aged mouse oocytes and a cyclophosphamide-induced premature ovarian failure mouse model
The administered agents were dasatinib and quercetin, and the cocktail was associated with lower reactive oxygen species, preserved spindle integrity and mitochondrial membrane potential, and improved fertility outcomes in the mouse model. In its discussion of concentration selection the paper cited published reports that nicotinamide mononucleotide at its higher tested concentrations reduced the number of matured oocytes in aged mice, and that Epitalon above its effective concentration range failed to rescue reactive oxygen species accumulation in post-ovulatory aged oocytes. Neither Epithalon nor an NAD+ precursor was administered in this study.
- 03Review2025
The Common Hallmarks and Interconnected Pathways of Aging, Circadian Rhythms, and Cancer: Implications for Therapeutic Strategies
Wang J, et al. · Research (Washington, D.C.) · narrative review of shared hallmarks and pathways linking ageing, circadian rhythm and cancer
The review reported that in rats housed under constant or natural light, which showed accelerated ageing, reduced mean and maximum lifespan and faster spontaneous tumour development, the Ala-Glu-Asp-Gly peptide and melatonin alleviated some of the effects of circadian disruption on lifespan and tumour development. In its metabolic section it described NAD+ as a coenzyme central to energy metabolism whose levels decline with age after puberty, with consequences for mitochondrial function. The two were placed in different sections of one framework rather than compared.
- 04Review2025
A State-of-the-Art Overview on (Epi)Genomics and Personalized Skin Rejuvenating Strategies
Tauser RG, et al. · Pharmaceutics · narrative review of genomic and epigenomic markers and intervention strategies in skin ageing
The review listed epitalon, described as a synthetic tetrapeptide composed of Ala-Glu-Asp-Gly, among the antioxidants tested to alleviate mitochondrial oxidative stress in skin, alongside resveratrol, quercetin, coenzyme Q10 and melatonin. Separately it grouped NAD+ boosters, naming nicotinamide riboside and nicotinamide mononucleotide, with telomerase activators as strategies intended to slow DNA damage accumulation, and stated that direct evidence in human skin is limited and that the effects of the NAD+ precursors may be systemic rather than cutaneous.
- 05Review2024
Biomedicines in Longevity and Aging the Quest to Resist Biological Decline
Palmer RD · BioMedicine · narrative review of biomedical interventions proposed to slow biological decline
The review described Epithalon, also written epitalon, as a tetrapeptide of the sequence Ala-Glu-Asp-Gly reported to induce expression of the telomerase catalytic subunit and associated enzymatic activity, and to regulate the pineal gland, retina and brain and induce neuronal differentiation in retinal and periodontal ligament stem cells. In a separate section it identified loss of essential coenzymes including nicotinamide adenine dinucleotide as a cellular insult of ageing, and carried nicotinamide mononucleotide in its abbreviation list. The two were surveyed as unrelated approaches.
- 06Review2020
Thymus-Pineal Gland Axis: Revisiting Its Role in Human Life and Ageing
Rezzani R, et al. · International Journal of Molecular Sciences · narrative review of the thymus-pineal gland axis in human development and ageing
The review recorded that research on pineal peptides was largely abandoned after the early 1980s except for the work of Khavinson and colleagues on the tetrapeptide Ala-Glu-Asp-Gly, named epitalon, and stated that despite numerous publications the sites of action of these peptides within the endocrine hierarchy remain to be clarified. In its oxidative stress section it described reactive oxygen species lowering the concentration of NAD+, the substrate and activator of the sirtuins, of which SIRT1 acts as an amplitude-enhancing component of circadian oscillators.
- 07Review2017
Current Perspective in the Discovery of Anti-aging Agents from Natural Products
Ding AJ, et al. · Natural Products and Bioprospecting · narrative review with a tabulated catalogue of compounds reported to extend lifespan in model organisms, indexed by CAS number, organism and reported mechanism
The catalogue listed Epitalon as producing an increase of about 17 percent in mean lifespan in Drosophila melanogaster with an antioxidant mechanism, and listed nicotinamide adenine dinucleotide as producing an increase of about 15 percent in mean lifespan in Caenorhabditis elegans through regulation of SIR-2.1 and DAF-16, with beta-nicotinamide mononucleotide entered separately as raising NAD+ levels in rats. The two appear as adjacent rows of one table without any experiment comparing them.
- 08Review2014
Effect of antioxidants supplementation on aging and longevity
Sadowska-Bartosz I, Bartosz G · BioMed Research International · narrative review of antioxidant supplementation studies in model organisms and humans, with tabulated lifespan outcomes
The review described Epitalon as a synthetic tetrapeptide, Ala-Glu-Asp-Gly, with antioxidant activity, and tabulated the reported increase of roughly 11 to 16 percent in Drosophila melanogaster lifespan among its model-organism results. NAD+ appeared in the review only as the cofactor defining the sirtuin family of NAD+-dependent protein deacetylases, invoked to explain why lifespan extension by apple procyanidins in Caenorhabditis elegans depended on SIR-2.1. No NAD+ precursor was evaluated as an intervention.
Side by side.
| Epithalon | NAD+ | |
|---|---|---|
| Evidence maturity | Early clinical | Early clinical |
| Studies cited here | 15 | 15 |
| Published 2023 or later | 8 | 11 |
| Newest paper | 2026 | 2026 |
| Molecular class and origin | A synthetic four-residue peptide, Ala-Glu-Asp-Gly, developed from the pineal gland extract preparation Epithalamin. It is not an endogenous human molecule in its own right. | Not a peptide but a pyridine nucleotide coenzyme present in every cell, functioning as a redox carrier and as the substrate consumed by sirtuins, PARPs and CD38. |
| Mechanism as described in the literature | Reported to induce telomerase activity and telomere elongation in cultured human cells, to modulate circadian and pineal gene expression and melatonin output, and to bind histone proteins and DNA in molecular modelling, which the authors proposed as an epigenetic mechanism. | Described as a substrate-availability problem. Tissue NAD+ falls with age in preclinical models, and sirtuins, PARPs and CD38 compete for the same pool, so interventions aim to raise the pool rather than to act on a receptor. |
| What is actually administered | The synthetic tetrapeptide itself, in the in vitro and animal work. The human longevity reports that are most often cited used the pineal extract preparation Epithalamin rather than the tetrapeptide. | Almost never NAD+ itself, which is poorly absorbed orally. Human trials use the precursors nicotinamide riboside and nicotinamide mononucleotide, so the human evidence describes precursor administration rather than the molecule named on the label. |
| Size of the evidence base | Fifteen verified studies in this library, weighted toward laboratory work: eight in vitro, three animal in vivo, two reviews and two human clinical reports. | Fifteen verified studies in this library, weighted toward controlled human research: eleven human clinical studies and two systematic reviews against a single animal in vivo report. |
| Human data | No published randomised, placebo-controlled, registered clinical trial of the synthetic tetrapeptide exists. The two human records are an open non-randomised follow-up study using the Epithalamin extract preparation and a buccal epithelium study published in a Russian gerontology journal. | Repeated randomised, double-blind, placebo-controlled trials. These consistently show that oral precursors raise circulating NAD+ two- to threefold and are well tolerated for up to about six months, while functional endpoints are inconsistent and meta-analyses of muscle, glucose and lipid outcomes have been null. |
| Evidence maturity | Early clinical, and only nominally so: the controlled trial record is absent, independent replication is confined to a small number of recent in vitro papers, and most of the corpus originates from one research institute publishing largely in Russian-language journals. | Early clinical. Trial designs are strong and independent groups have replicated the pharmacokinetic finding, but no trial has demonstrated a durable clinical benefit, so the maturity is in the methods rather than in the outcomes. |
| Best-characterised finding | Induction of telomerase activity and telomere elongation in human somatic cell culture at the Hayflick limit, first reported in 2003 and revisited in an independent 2025 cell-line study that attributed the effect to telomerase upregulation in normal cells and to alternative lengthening of telomeres in cancer lines. | A reliable, reproducible rise in blood NAD+ after oral nicotinamide riboside or nicotinamide mononucleotide, demonstrated across multiple randomised trials and dissociated from improvement in cognition, muscle function, glycaemic control or blood pressure. |
| Principal open safety question | Whether telomerase induction carries oncological risk. Human pharmacokinetics, dose-response and long-term safety are uncharacterised, and the 2025 cell-line work reported telomere lengthening in cancer lines as well as normal cells. | Long-term exposure beyond about six months, which no trial has examined. Within that window a 2026 meta-analysis of fifteen randomised trials found no increase in overall, serious or system-specific adverse events and no elevation of liver enzymes. |
And what it does not.
Nothing in the published record establishes how these two compare, because no experiment has run them side by side and none has combined them. What the separate literatures support is asymmetric in an unusual way. Epithalon has the more striking claims, telomerase induction and lifespan extension, resting on a corpus dominated by one research institute, published largely in Russian-language journals, with almost no independent replication outside a handful of recent in vitro papers and no registered randomised trial of the tetrapeptide in humans at all. NAD+ has the stronger method: repeated randomised, double-blind, placebo-controlled trials that reliably demonstrate its oral precursors raise circulating NAD+ and are well tolerated. That strength is also what makes its limits clear, since the same trials have failed to convert the biochemical change into durable improvements in muscle, cognition, glycaemic control or blood pressure, and meta-analyses of those endpoints are null. Neither compound has human evidence that it slows biological ageing, which is the claim that prompts the comparison.
Common questions.
- Has any study tested Epithalon and NAD+ in the same experiment?
No such study was located in PubMed or Europe PMC, in any model or species, and no combination study exists either. The publications that engage both are geroprotection reviews that catalogue the AEDG tetrapeptide and nicotinamide riboside or nicotinamide mononucleotide as separate entries in one landscape, sometimes in adjacent rows of the same table, plus one 2025 mouse oocyte study whose discussion cited published results for each while administering neither. Every comparison between them is therefore assembled from unrelated experiments.
- What did the systematic review that tabulated both actually record?
A 2023 systematic review of sex differences in rodent lifespan interventions listed both. Epithalon, injected into female CBA mice, was recorded as increasing mean lifespan with improvement in several healthspan measures, and the review noted that no male comparison existed. Nicotinamide riboside produced a split record: increased maximal lifespan in one C57BL/6 study that did not report sex, and no lifespan effect in either sex in a later UM-HET3 study. The review's own conclusion concerned method, that single-sex and single-strain designs limit what such results support.
- Are the two aimed at the same hallmark of ageing?
As the literature describes them, no. Epithalon is studied against telomere attrition and circadian and pineal decline, with reported telomerase induction, telomere elongation in cultured cells and modulation of melatonin output. NAD+ is studied against metabolic and mitochondrial decline, framed as loss of substrate availability for sirtuins, PARPs and CD38 rather than as action on a receptor. One skin-ageing review grouped NAD+ boosters with telomerase activators as strategies against DNA damage accumulation, but that grouping is editorial rather than experimental.
- Why does most NAD+ human research involve nicotinamide riboside or nicotinamide mononucleotide rather than NAD+ itself?
Because NAD+ is poorly absorbed when taken orally, so the trials use precursors that the body converts. Randomised evidence shows nicotinamide riboside and nicotinamide mononucleotide comparably raise circulating NAD+ while nicotinamide does not, and a 2026 study indicated that gut microbiota convert both precursors to nicotinic acid, which was the potent direct booster in whole blood. This matters for interpretation: the human data describe what precursor supplementation does, not what administering the cofactor itself would do.
- Which of the two has stronger independent replication?
NAD+, by a wide margin. The finding that oral precursors raise circulating NAD+ has been reproduced by separate groups across randomised trials in healthy adults, older adults, prediabetic women, peripheral artery disease and long COVID, and the null functional results have been pooled in independent meta-analyses. The Epithalon corpus is dominated by the St Petersburg Institute of Bioregulation and Gerontology, and the independent work that does exist, published between 2022 and 2025, is confined to cell and oocyte culture.
For research purposes only. Not for human consumption, diagnosis, treatment, or prevention of any condition. Nothing on this page is medical advice, and no comparison here should be read as a recommendation of either compound.